{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:32:32Z","timestamp":1778931152837,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["357"],"award-info":[{"award-number":["357"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1095741"],"award-info":[{"award-number":["OPP1095741"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009527","name":"Statens Serum Institut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009527","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.02.066","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T17:11:30Z","timestamp":1586193090000},"page":"3780-3789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15\u201318\u00a0months"],"prefix":"10.1016","volume":"38","author":[{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Thierry-Carstensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina Saem","family":"Stoey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Wachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-2001","authenticated-orcid":false,"given":"Ananda S.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille Ingemann","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie Vestergaard","family":"Kusk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.066_b0005","unstructured":"Global Polio Eradication Initiative. Wild poliovirus list. 2019. Accessed 31Jan2020. http:\/\/polioeradication.org\/polio-today\/polio-now\/wild-poliovirus-list\/."},{"key":"10.1016\/j.vaccine.2020.02.066_b0010","unstructured":"Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared.. 2015. Accessed 31Jan2020. http:\/\/polioeradication.org.\/news-post\/global-eradication-of-wild-poliovirus-type-2-declared\/."},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.066_b0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.vaccine.2020.02.066_b0020","unstructured":"World Health Organization. Weekly epidemiological record. Meeting of the SAGE group on immunization, April 2019- conclusions and recommendations.. 2019. Accessed 16Oct2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325017\/WER9422-23-en-fr.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2020.02.066_b0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1473-3099(17)30177-9","volume":"17","author":"Rivera","year":"2017","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.066_b0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.vaccine.2019.10.064","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age","volume":"38","author":"Bravo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.vaccine.2016.12.027","volume":"35","author":"Lindgren","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0040","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"ethical principles for medical research involving human subjects","volume":"284","author":"World Medical Association Declaration of Helsinki","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.02.066_b0045","unstructured":"International Conference on Harmonisation. ICH Harmonised guideline. Integrated addendum to ICH E6(1): guideline for good clinical practice E6(R2). 2016. Accessed 16Oct2019. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf."},{"key":"10.1016\/j.vaccine.2020.02.066_b0050","unstructured":"Robertson S. Module 6: Poliomyelitis. In: The Immunological Basis for Immunization Series, WHO. 1993. Accessed 16Oct2019. http:\/\/www.who.int\/ihr\/polio1993en.pdf."},{"key":"10.1016\/j.vaccine.2020.02.066_b0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4049\/jimmunol.74.1.71","article-title":"The effect of gamma globulin on subclinical infection in familial associates of poliomyelitis cases. II Serological Studies and Virus Isolations from Pharyngeal Secretions","volume":"74","author":"Brown","year":"1955","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2020.02.066_b0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2020.02.066_b0065","doi-asserted-by":"crossref","unstructured":"Melnick JL. Enteroviruses. In: AS E, editor. Viral infections of humans: Epidemiology and control. Switzerland: Springer Nature; 1984. p. 187-251.","DOI":"10.1007\/978-1-4684-4727-9_9"},{"key":"10.1016\/j.vaccine.2020.02.066_b0070","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1016\/S0264-410X(03)00420-1","volume":"21","author":"Aristegui","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/01.inf.0000145427.19167.35","article-title":"Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type B vaccine","volume":"23","author":"Tejedor","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.066_b0080","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.inf.0000227725.61495.c4","volume":"25","author":"Tejedor","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.066_b0085","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/00006454-200110000-00011","article-title":"Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants","volume":"20","author":"Yeh","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.066_b0090","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.vaccine.2016.02.010","article-title":"Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China","volume":"34","author":"Li","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0095","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.vaccine.2018.03.021","article-title":"A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vacci","volume":"36","author":"Marlow","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0100","unstructured":"Glaxo Smith Kline. Infanrix Hexa - Product Monopraph. 2018. Accessed 16Oct2019. https:\/\/ca.gsk.com\/media\/537989\/infanrix-hexa.pdf"},{"key":"10.1016\/j.vaccine.2020.02.066_b0105","unstructured":"Sanofi Pasteur. Hexaxim - Summary of Product Characteristics. EMA. 2018. Accessed 16Oct2019. https:\/\/www.ema.europa.eu\/documents\/medicine-outside-eu\/hexaxim-product-information_en.pdf."},{"key":"10.1016\/j.vaccine.2020.02.066_b0110","doi-asserted-by":"crossref","unstructured":"Siegrist C-A. Vaccine Immunology. In: Plotkin, Stanley. Orensterin, W. Offit P et al, editor. Plotkin\u2019s Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 16\u201334.","DOI":"10.1016\/B978-0-323-35761-6.00002-X"},{"key":"10.1016\/j.vaccine.2020.02.066_b0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/infdis\/168.2.452","article-title":"Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines","volume":"168","author":"Faden","year":"1993","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.02.066_b0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0264-410X(90)90244-G","article-title":"Polio immunity to killed vaccine: an 18-year follow-up","volume":"8","author":"B\u00f6ttiger","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0125","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1016\/j.vaccine.2008.07.033","article-title":"Safety and immunogenicity of a DTaP-IPVVero (serum-free) combination vaccine in comparison to DTaP-IPVMkc when administered simultaneously with Haemophilus influenzae type b conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age","volume":"26","author":"Pietrzyk","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/00365549950164472","article-title":"Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine","volume":"31","author":"Gyhrs","year":"1999","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.066_b0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.vaccine.2003.09.011","article-title":"Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells","volume":"22","author":"Haastrup","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0140","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.vaccine.2013.08.034","article-title":"Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults\u2013a review of safety, immunogenicity, efficacy and effectiveness trials and 15 years of field experience","volume":"31","author":"Thierry-Carstensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0145","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2012.06.073","volume":"30","author":"Thierry-Carstensen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0150","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1016\/j.vaccine.2012.09.059","article-title":"Adjuvants and inactivated polio vaccine: a systematic review","volume":"30","author":"Hawken","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.066_b0155","series-title":"Plotkin\u2019s Vaccines","first-page":"841","article-title":"Poliovirus Vaccine-Inactivated","author":"Vidor","year":"2018"},{"key":"10.1016\/j.vaccine.2020.02.066_b0160","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapediatrics.2017.0638","article-title":"The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis","volume":"171","author":"Voysey","year":"2017","journal-title":"JAMA Pediatrics"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2020.02.066_b0165","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/ciy649","article-title":"Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the Polio Eradication Endgame","volume":"67","author":"Gaensbauer","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6199","key":"10.1016\/j.vaccine.2020.02.066_b0170","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. Efficacy of inactivated poliovirus in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"issue":"9953","key":"10.1016\/j.vaccine.2020.02.066_b0175","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","article-title":"Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial","volume":"384","author":"John","year":"2014","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:38Z","timestamp":1759401818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":35,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20302954"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15\u201318\u00a0months","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}